🇺🇸 FDA
Patent

US 11135280

Modified ebolavirus glycoproteins comprising mutations in the head and base domains that increase antibody cross-reactivity

granted A61KA61K39/12

Quick answer

US patent 11135280 (Modified ebolavirus glycoproteins comprising mutations in the head and base domains that increase antibody cross-reactivity) held by INTEGRATED BIOTHERAPEUTICS, INC. expires Mon Sep 30 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
INTEGRATED BIOTHERAPEUTICS, INC.
Grant date
Tue Oct 05 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 30 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
13
CPC classes
A61K, A61K39/12